Arina Yespotayeva

Arina Yespotayeva

Auto-generated profile, based on publicly available information

Arina Yespotayeva

Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University, Almaty, Kazakhstan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in Central Asian Journal of Nephrology
Verified
Journal Article
Closed access
GCGulnar Chingayeva
Gulnar Chingayeva
DKDina Karibayeva
Dina Karibayeva
AIAssel Issenova
Assel Issenova
ASAbay Shepetov
Abay Shepetov
NMNagima Mustapayeva
Nagima Mustapayeva
AYArina Yespotayeva
Arina Yespotayeva
Background: Immunoglobulin A nephropathy is among the most commonly observed glomerular disorders. Its development is associated with immune dysfunction, which initiates a cascade of pathological changes within the glomeruli. The clinical course can range from minimal urinary abnormalities to progressive renal impairment, potentially culminating in end-stage kidney disease. Despite considerable advances in understanding its pathogenesis, optimal therapeutic strategies remain an active focus of scientific investigation. Aim: To assess current and emerging therapeutic strategies for IgA nephropathy, with an emphasis on efficacy, safety, and the potential of targeted agents addressing key pathogenic pathways. Methods: We conducted a narrative review of recent literature in PubMed, Scopus, Web of Science, and eLIBRARY databases, focusing on publications from the last decade. Studies published in English and Russian that reported results from clinical trials or meta-analyses on therapeutic interventions for IgA nephropathy were included. Search terms included «IgA nephropathy», «treatment», «targeted therapy», «new therapies», «immunosuppressants», and «clinical trials». Priority was given to randomized controlled trials and studies with high-quality evidence, though relevant observational data were also considered. Results: Key studies identified included 52 publications, among which 20 were randomized clinical trials and a systematic review. Corticosteroid therapy remains a cornerstone of treatment but is limited by significant adverse effects. Recent therapeutic developments in IgA nephropathy have focused on interventions that selectively target inflammatory and immune pathways involved in disease progression. Certain novel agents aimed at modulating immune signaling or addressing pathogenic plasma cells have shown potential to reduce proteinuria and stabilize renal function. Early-phase clinical investigations indicate promising efficacy and manageable safety profiles, suggesting these approaches may represent important advances in disease management. Conclusions: Recent progress in targeted and immunomodulatory therapies offers new perspectives for personalized treatment of IgA nephropathy. Comprehensive, large-scale randomized studies with extended follow-up are warranted to thoroughly assess the therapeutic potential, safety profile, and optimal positioning of these interventions within future clinical management strategies.

1 June 2020 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
AYArina Yespotayeva
Arina Yespotayeva
KKKairat Kabulbayev
Kairat Kabulbayev
AGAbduzhappar Gaipov
Abduzhappar Gaipov
ZAZauresh Amreyeva
Zauresh Amreyeva
ZMZhanar Mursalova
Zhanar Mursalova
Background and Aims: Patients getting maintenance haemodialysis (HD) are at higher risk for acquiring Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections than the general population. Strict infection control measures are essential to prevent nosocomial transmission. We aimed to investigate the incidence and prevalence of HBV and HCV infection in the HD population of Almaty dialysis units as well as risk factors for infection. Method: All adult patients getting maintenance HD (n=700) in Almaty dialysis centres (n=4) were studied between May 2016 and December 2019. Testing for Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies was performed at initiation of dialysis and every 3–6 months thereafter. Serological markers for HBV and HCV were determined with immunoenzymatic assay (ELISA). Results: Participant median age was 40 years and 58% were male. 110 patients (34.9%) were sero-positive for HBV and/or HCV (anti-HCV positive 31.1%; HBsAg positive 2.6%; both positive 1.2%). Of the sero-positive patients 4.7% were known to be infected before the initiation of HD. The prevalence of HBV±HCV infection varied widely between HD centres from 0% to 75.9%. Sero-positive patients were younger, had longer time on dialysis and more previous blood transfusions. Wide variation in rates of newly acquired infections was observed between dialysis centres. All new HBV cases were referred from centres already treating HBV infected patients. New HCV infections were reported in most centres but the rate of HCV sero-conversion varied widely from 1.5% to 31%. Duration of dialysis, history of previous renal transplant and history of receiving HD in another centre in Almaty were significantly associated with sero-conversion. Major risk factors identified by a standard questionnaire in 302 of 270 patients were the number of blood transfusions individuals had received and duration of dialysis, the latter including patients who received no blood transfusions Conclusion: HBV and HCV prevalence in our HD patients is still high. These data emphasize the need for stricter adherence to infection control, barrier precaution and preventive behaviors with all patients. In summary, the prevalence of HBV and HCV in our HD patients is still high. These data emphasize the need for stricter adherence to infection control, barrier precaution and preventive behaviors with all patients.

22 May 2025 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
AYArina Yespotayeva
Arina Yespotayeva
KKKairat Kabulbayev
Kairat Kabulbayev
Almagul KurmanovaAlmagul Kurmanova
Almagul Kurmanova
ANAlexander V Nersesov
Alexander V Nersesov
ARAigul Raissova
Aigul Raissova
AGAisulu Gainutdin
Aisulu Gainutdin
Background and aims: Chronic viral hepatitis, including Hepatitis B (HBV) and Hepatitis C (HCV), remains a major health concern among hemodialysis patients. This study analyzes the prevalence and characteristics of HBV and HCV infections in hemodialysis patients treated at a single center in Almaty, focusing on comorbidities such as diabetes, hypertension, and cirrhosis. This study aims to determine the prevalence of these infections among hemodialysis patients in Kazakhstan and assess their associated comorbidities, complications, and overall impact on patient health. Methods: Data from the Almaty Center of Hepatology (2016–2023) served as the basis for the study cohort. Inclusion criteria included CKD stage 5, hemodialysis dependence, ESRD, and confirmed HBV, HCV, or both. The study consists of 164 patients diagnosed with HBV, HCV, or mixed infections, with data collected on demographic distribution, viral genotype prevalence, fibrosis staging, and associated conditions. Results: The findings highlight a substantial prevalence of comorbid conditions in hemodialysis patients with viral hepatitis. The study population includes 95 males (57.9%) and 69 females (42,1%), with a slight male predominance. HCV was the most common infection (76.8%), followed by HBV (14%) and mixed HCV+HBV (9.2%). The high percentage of an unspecified genotype (36.4%) suggests that enhanced diagnostic strategies are needed. Cirrhosis was observed in nearly 90% of the cohort, and 92.7% exhibited ascites. Fibrosis progression was significant, with 25.5% of patients in stage 1, 24.2% in stage 2, and 18.8% in stage 3. The prevalence of hypertension (53.9% with high-risk stage 3 hypertension), diabetes (14.5% with type 2 diabetes), and cirrhosis (89.7%) was assessed. Additionally, hepatitis genotypes were identified, with HCV genotype three being the most common (18.2%) and genotype 1 (17.6%). Conclusions: The results of this study demonstrate that patients on hemodialysis with viral hepatitis represent a particularly vulnerable group with a high incidence of severe liver damage and multiple comorbidities. The high rates of advanced fibrosis, cirrhosis, and associated conditions such as hypertension and diabetes underscore the need for timely diagnosis and complex, patient-centered care

30 April 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
AYA. Yespotayeva
A. Yespotayeva
KKK. Kabulbayev
K. Kabulbayev
Almagul KurmanovaAlmagul Kurmanova
Almagul Kurmanova
AGA. Gaipov
A. Gaipov
ANAlexander V Nersesov
Alexander V Nersesov
SKS. Karmakbayev
S. Karmakbayev
Background: Patients with end-stage renal disease (ESRD) undergoing hemodialysis represent a high-risk group for chronic viral hepatitis and its complications. The development of pangenotypic direct-acting antivirals (DAAs) has significantly improved the prognosis of hepatitis C virus (HCV) infection in this population. However, local data from Central Asia, particularly Kazakhstan, remain limited. Aim: To evaluate the efficacy and safety of antiviral therapy in a subgroup of 12 patients with chronic hepatitis B and/or C receiving maintenance hemodialysis at the Hepato Center in Almaty. Methods: From a larger cohort of 164 hemodialysis patients with confirmed viral hepatitis, 12 patients received antiviral treatment between 2021 and 2023. Treatment regimens included pangenotypic DAAs for HCV (Sofosbuvir/Velpatasvir) and nucleos(t)ide analogs for HBV (entecavir or tenofovir). Sustained virological response (SVR12 and SVR24), liver function parameters, fibrosis regression (assessed via FibroScan), and adverse events were recorded. Results: Of the 12 patients, 9 were HCV-positive (genotypes 1, 1b, or 3), 2 had HBV, and 1 had mixed HBV+HCV infection. All HCV patients were treated with SOF/VEL for 8–12 weeks. SVR12 and SVR24 were achieved in 100% of HCV-treated patients. The two HBV patients showed complete viral suppression after 24 weeks of treatment. One mixed-infection patient achieved full suppression of both viruses. FibroScan results showed fibrosis improvement in 7 of 10 patients re-evaluated post-treatment. Liver enzymes normalized in 11 patients. No severe adverse events occurred; two patients reported mild pruritus, and no anemia-related complications were observed. Conclusion: Antiviral therapy with pangenotypic DAAs and nucleos(t)ide analogs was highly effective and well tolerated in hemodialysis patients with chronic hepatitis B and C. These findings demonstrate the feasibility and clinical benefit of integrating antiviral treatment into routine nephrology care for dialysis-dependent patients in Kazakhstan. Актуальность: Пациенты с терминальной стадией хронической болезни почек (ХБП), получающие лечение программным гемодиализом, относятся к группе высокого риска по хроническим вирусным гепатитам и связанным с ними осложнениям. Разработка пангенотипных противовирусных препаратов прямого действия (ПППД) значительно улучшила прогноз у пациентов с инфекцией вируса гепатита C (ВГС) в данной популяции. Однако локальные данные по Центральной Азии, особенно по Казахстану, остаются ограниченными. Цель: оценить эффективность и безопасность противовирусной терапии у подгруппы из 12 пациентов с хроническим гепатитом B и/или C, получающих программный гемодиализ в Гепатоцентре Алматы. Методы: из общей когорты из 164 пациентов на гемодиализе с подтвержденным вирусным гепатитом 12 человек прошли противовирусное лечение в период с 2021 по 2023 год. Схемы терапии включали пангенотипные ПППД для ВГС (софосбувир + велпатасвир) и аналоговые нуклеозиды/нуклеотиды для ВГВ (энтековир или тенофовир). Оценивались устойчивый вирусологический ответ (УВО12 и УВО24), показатели функции печени, регресс фиброза (по данным ФиброСкана) и нежелательные явления. Результаты: Из 12 пациентов у 9 был диагностирован ВГС (генотипы 1, 1b или 3), у 2 - ВГВ, и у 1 пациента – смешан-ная инфекция ВГВ+ВГС. Все пациенты с ВГС получали софосбувир /велпатасвир в течение 8–12 недель. УВО12 и УВО24 были достигнуты у 100% пациентов с ВГС. У двух пациентов с ВГВ через 24 недели терапии была достигнута полная супрессия вируса. Пациент со смешанной инфекцией достиг полной супрессии обоих вирусов. По данным ФиброСкана улучшение фиброза было зафиксировано у 7 из 10 пациентов, проходивших повторное обследование. Нормализация печеночных ферментов (АЛТ/АСТ) произошла у 11 пациентов. Серьезных нежелательных явлений не зарегистрировано; два пациента жаловались на умеренный кожный зуд, анемия или связанные с ней осложнения не наблюдались. Вывод: Противовирусная терапия пангенотипными ПППД и аналогами нуклеозидов/нуклеотидов оказалась высокоэффективной и хорошо переносимой у пациентов на гемодиализе с хроническими гепатитами B и C. Полученные результаты подтверждают целесообразность и клиническую...